A Study to Evaluate the Impact of a Pharmacist-led Oral Anticancer Medication (OAM) Program on Patient Outcomes

Overview

About this study

The purpose of this study is to evaluate the impact of integrating a pharmacist-led OAM education program within the interdisciplinary oncology team at the Stephen and Barbara Slaggie Family Cancer Center and Blood Disorders Center within Mayo Clinic Health System – La Crosse.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patient age ≥ 18 years.
Patients seen at Stephen and Barbara Slaggie Family Cancer Center and Blood Disorders Center within Mayo Clinic Health System – La Crosse, being initiated on OAM therapy.

Exclusion Criteria:

Any patient who had previously received oral anti-cancer (OAM) therapy.
Patient age < 18 years.
Pregnancy.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
La Crosse, Wis. Mayo Clinic principal investigator Mary Gilmer, Pharm.D., R.Ph., M.H.A.	Closed for enrollment	Contact information: Katharine Damico Pharm.D., R.Ph. (608) 392-2894 Damico.Katharine@mayo.edu

Mayo Clinic Location

Status

Contact

La Crosse, Wis.

Mayo Clinic principal investigator

Mary Gilmer, Pharm.D., R.Ph., M.H.A.

Closed for enrollment

Contact information:

Katharine Damico Pharm.D., R.Ph.

(608) 392-2894

Damico.Katharine@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials